文献速递细胞病理与分子病理神经与头颈病理

米兰系统在囊性唾液腺病变细胞病理中的应用

Application of the Milan System for Reporting Salivary Gland Cytopathology to cystic salivary gland lesions.
PubMed 文献 · Cancer Cytopathol · 2020-10-01

该研究回顾性分析约翰霍普金斯医院19年间178例囊性唾液腺细针穿刺标本,应用米兰报告系统(MSRSGC)分类并计算恶性肿瘤风险(ROM)和肿瘤风险(RON)。结果显示SFM类别ROM为100%,SUMP为50%,AUS为29.4%,非诊断性为22.2%,非肿瘤性为19%。应用MSRSGC有助于避免非肿瘤性病变的不必要手术。

要点

  • 囊性唾液腺FNA应用MSRSGC可提高诊断规范性并指导临床管理。
  • SFM类别ROM达100%,SUMP为50%,AUS为29.4%,需警惕恶性可能。
  • 标本不足可能增加AUS诊断,应关注取材质量。

核心结论

  • 应用MSRSGC对囊性唾液腺病变进行分类可改善患者管理,避免非肿瘤性病变的不必要手术。
  • ROM在SFM类别最高(100%),其次为SUMP、AUS、非诊断性和非肿瘤性类别。
  • 标本不足可能增加AUS的诊断。

研究设计与样本

  • 回顾性研究,检索约翰霍普金斯医院2000-2018年共19年的囊性唾液腺FNA标本。
  • 共纳入178例病例(96例男性,82例女性),平均年龄53岁(范围4-90岁)。
  • 记录患者人口学特征、细胞形态学特征及临床和手术随访资料,并应用MSRSGC分类。
  • 计算每个类别的恶性肿瘤风险(ROM)和肿瘤风险(RON)。

主要发现

  • MSRSGC分类结果:非诊断性52例(29.2%),非肿瘤性80例(44.9%),AUS 35例(19.7%),良性肿瘤3例(1.7%),SUMP 3例(1.7%),SFM 4例(2.2%),恶性1例(0.6%)。
  • 有手术随访的病例中,非诊断性类别RON为33.3%(3/9),ROM为22.2%(2/9)。
  • 非肿瘤性类别RON为42.9%(9/21),ROM为19%(4/21);AUS类别RON为76.5%(13/17),ROM为29.4%(5/17)。
  • SUMP类别RON为100.0%(2/2),ROM为50.0%(1/2);SFM类别RON和ROM均为100%(2/2)。

临床怎么用

  • 对囊性唾液腺FNA应用MSRSGC分类,有助于识别非肿瘤性病变,避免不必要的手术。
  • 对于AUS、SUMP和SFM类别,应结合临床和影像学谨慎评估恶性风险。
  • 注意标本取材质量,减少因标本不足导致的AUS诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cystic salivary gland lesions present diagnostic challenges on fine-needle aspiration (FNA) specimens that are related to sampling limitations and a broad differential diagnosis. This study evaluated the benefit of applying the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) to a series of cystic salivary gland lesions. METHODS: The pathology archives at the Johns Hopkins Hospital were searched to identify cystic salivary gland FNA specimens over a 19-year period (2000-2018). Patient demographics, cytomorphologic features, and clinical and surgical follow-up were recorded. The MSRSGC was applied to the cases. The risk of malignancy (ROM) and the risk of neoplasia (RON) were calculated for each category. RESULTS: One hundred seventy-eight cases were identified (96 males and 82 females) with a mean age of 53 years (range, 4-90 years). After the MSRSGC was applied, there were 52 nondiagnostic cases (29.2%), 80 nonneoplastic cases (44.9%), 35 cases of atypia of undetermined significance (AUS; 19.7%), 3 benign neoplasms (1.7%), 3 salivary gland neoplasms of uncertain malignant potential (SUMP; 1.7%), 4 cases suspicious for malignancy (SFM; 2.2%), and 1 malignant case (0.6%). One hundred fifty-six of the 178 patients (87.6%) had follow-up data available. The RON and ROM values for cases with surgical follow-up were 33.3% (3 of 9) and 22.2% (2 of 9) for the nondiagnostic category, 42.9% (9 of 21) and 19% (4 of 21) for the nonneoplastic category, 76.5% (13 of 17) and 29.4% (5 of 17) for the AUS category, 100.0% (2 of 2) and 50.0% (1 of 2) for the SUMP category, and 100% (2 of 2) and 100% (2 of 2) for the SFM category, respectively. CONCLUSIONS: Applying the MSRSGC to cystic salivary gland lesions improves patient management by preventing unnecessary surgery for nonneoplastic conditions. The ROM was highest in the SFM category (100%), which was followed by the SUMP, AUS, nondiagnostic, and nonneoplastic categories. Less than adequate specimens may increase the diagnosis of AUS.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Maleki Z, Allison DB, Butcher M, et al. Application of the Milan System for Reporting Salivary Gland Cytopathology to cystic salivary gland lesions. Cancer Cytopathol. 2020. PMID: 33002347. doi:10.1002/cncy.22363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。